Korean J Gastroenterol.  2015 Jun;65(6):384-385. 10.4166/kjg.2015.65.6.384.

Efficacy and Safety of an Oral SMAD7 Antisense Drug for Active Crohn's Disease

• Seo GS

• KMID: 2373243
• DOI: http://doi.org/10.4166/kjg.2015.65.6.384

Abstract

No abstract available.

MeSH Terms

Crohn Disease/*drug therapy
Female
Humans
Immunosuppressive Agents/*administration & dosage
Male
Oligonucleotides/*administration & dosage
Smad7 Protein/*antagonists & inhibitors
Immunosuppressive Agents
Oligonucleotides
Smad7 Protein

Reference

References

1. Monteleone G, Neurath MF, Ardizzone S, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med. 2015; 372:1104–1113.

2. Kulkarni AB, Karlsson S. Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dra-matic inflammatory disease. Am J Pathol. 1993; 143:3–9.

3. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 2000; 12:171–181.

4. Neurath MF, Fuss I, Kelsall BL, Presky DH, Waegell W, Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGFbeta-mediated oral tolerance. J Exp Med. 1996; 183:2605–2616.

5. Kitani A, Fuss IJ, Nakamura K, Schwartz OM, Usui T, Strober W. Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGFbeta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. J Exp Med. 2000; 192:41–52.

6. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGFbeta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001; 108:601–609.

7. Boirivant M, Pallone F, Di Giacinto C, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology. 2006; 131:1786–1798.

8. Zorzi F, Calabrese E, Monteleone I, et al. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease. Aliment Pharmacol Ther. 2012; 36:850–857.

9. Monteleone G, Fantini MC, Onali S, et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther. 2012; 20:870–876.

10. Colombel JF, Sandborn WJ, Reinisch W, et al. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362:1383–1395.

11. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130:323–333.

12. Vermeire S. Oral SMAD7 antisense drug for Crohn's disease. N Engl J Med. 2015; 372:1166–1167.